Oncology News

CHICAGO — The addition of nimotuzumab to gemcitabine prolonged OS and PFS among patients with KRAS wild-type locally advanced or metastatic pancreatic cancer, according to randomized phase 3 study results presented at ASCO Annual Meeting.

The percentage of patients presenting with late-stage breast and colorectal cancers increased between 2019 and 2020 at Moores Cancer Center at University of California San Diego Health, according to data published in JAMA Network Open.

The FDA approved nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as first-line treatments for adults with unresectable advanced or metastatic esophageal squamous cell carcinoma.

SAN DIEGO — A pilot study presented at Digestive Disease Week 2022 demonstrated that while voice assistants performed well in providing clinically accurate information on colorectal cancer screening, improvements are still needed.

SAN DIEGO — Pre-alert text message notification followed by mailed fecal immunochemical test kits improved population-level screening for colorectal cancer during COVID-19, according to research.

SAN DIEGO — Five-year relative survival for early-onset colorectal cancer improved over a 20-year period only among white patients, with no improvements for Black, Asian or Hispanic patients, per data at Digestive Disease Week 2022.

SAN DIEGO — Liver stiffness assessment predicted liver-related complications and hepatocellular carcinoma development among patients with hepatitis C following direct-acting antiviral treatment, according to research.

Excess weight had a stronger impact on colorectal cancer risk than suggested in previous studies that did not consider cumulative lifetime exposure, according to a study published in JAMA Oncology.

In this video exclusive, Aasma Shaukat, MD, MPH, professor at NYU Grossman School of Medicine, discusses how her group achieved diverse enrollment for PREEMPT CRC, a study designed to validate a blood test for colorectal cancer screening.

Patients with pancreatic ductal adenocarcinoma were six times more likely to have had cholelithiasis or cholecystitis in the year before diagnosis compared with the general population, according to data presented at Digestive Disease Week.